Advanced Ovarian Cancer Pipeline Insights LAS VEGAS, NV, UNITED STATES, February 12, 2025 /EINPresswire / -- As per DelveInsight's assessme ...

ExpressionEdits in Cambridge has clinched unspecified riches from global pharmaceutical company Boehringer Ingelheim through ...

ExpressionEdits' Genetic Syntax Engine platform is designed to enhance gene expression within gene therapies by restoring introns.

Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.

In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...

BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...

Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...

Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...